Comparative Pharmacology
Head-to-head clinical analysis: SEVELAMER CARBONATE versus VELPHORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEVELAMER CARBONATE versus VELPHORO.
SEVELAMER CARBONATE vs VELPHORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sevelamer carbonate is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. It also binds bile acids and may reduce LDL cholesterol.
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
Adults: 800 to 1600 mg orally three times daily with meals, titrated according to serum phosphorus targets.
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
None Documented
None Documented
Not applicable. Sevelamer carbonate is not systemically absorbed and thus has no measurable plasma half-life. Its pharmacological effect correlates with gastrointestinal transit time, which is typically 24-48 hours.
Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life).
Sevelamer carbonate is not absorbed systemically; it acts locally in the gastrointestinal tract. Excretion is entirely fecal, with no renal or biliary elimination. The polymer is excreted unchanged in the feces.
Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%).
Category A/B
Category C
Phosphate Binder
Phosphate Binder